- Home
- FGMC vs PLRX Comparison
FGMC vs PLRX Comparison
Compare FGMC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGMC
- PLRX
- Stock Information
- Founded
- FGMC 2023
- PLRX 2015
- Country
- FGMC United States
- PLRX United States
- Employees
- FGMC N/A
- PLRX N/A
- Industry
- FGMC
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FGMC
- PLRX Health Care
- Exchange
- FGMC NYSE
- PLRX Nasdaq
- Market Cap
- FGMC 98.9M
- PLRX 84.7M
- IPO Year
- FGMC 2025
- PLRX 2020
- Fundamental
- Price
- FGMC $9.78
- PLRX $1.44
- Analyst Decision
- FGMC
- PLRX Hold
- Analyst Count
- FGMC 0
- PLRX 10
- Target Price
- FGMC N/A
- PLRX $9.79
- AVG Volume (30 Days)
- FGMC 30.4K
- PLRX 1.0M
- Earning Date
- FGMC 01-01-0001
- PLRX 05-08-2025
- Dividend Yield
- FGMC N/A
- PLRX N/A
- EPS Growth
- FGMC N/A
- PLRX N/A
- EPS
- FGMC 0.08
- PLRX N/A
- Revenue
- FGMC N/A
- PLRX N/A
- Revenue This Year
- FGMC N/A
- PLRX N/A
- Revenue Next Year
- FGMC N/A
- PLRX N/A
- P/E Ratio
- FGMC $566.65
- PLRX N/A
- Revenue Growth
- FGMC N/A
- PLRX N/A
- 52 Week Low
- FGMC $9.53
- PLRX $1.10
- 52 Week High
- FGMC $9.85
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- FGMC N/A
- PLRX 46.88
- Support Level
- FGMC N/A
- PLRX $1.22
- Resistance Level
- FGMC N/A
- PLRX $1.41
- Average True Range (ATR)
- FGMC 0.00
- PLRX 0.09
- MACD
- FGMC 0.00
- PLRX 0.02
- Stochastic Oscillator
- FGMC 0.00
- PLRX 65.45
About FGMC FG MERGER II CORP
FG Merger II Corp is a blank check company, incorporated for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (Business Combination).
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.